21 August 2017
Visiongain’s new report The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography indicates that the SLE market will see over $570m in revenue in 2017.
The lead analyst of the report said:
“Systemic Lupus Erythematosus (SLE) is an autoimmune disease as the body's immune system mistakenly attacks healthy tissue. It affects the skin, joints, kidneys, brain, and other organs. Systemic Lupus Erythematosus is a chronic disease characterized with phases of worsening symptoms that alternate with periods of mild symptoms. Most people with Systemic Lupus Erythematosus lead a normal life with treatment. The term lupus used to identify a number of immune diseases that have homogenous clinical presentations and laboratory features, however Systemic Lupus Erythematosus is the most common type of lupus.
Currently, a lot of research activity is going on in the field of Systemic Lupus Erythematosus. There are around 60 molecules in active pipeline development. Many new therapies and mechanism of action are being tested in the pre-clinical stages or early stages like BTK, JAK inhibitors and T-cell modulator etc.
The current growth in Systemic Lupus Erythematosus market has also been fuelled by the therapies based on oral route of delivery. The diseases providing a greater benefit also commands a relatively higher price in the rare disease space.
The 152-page report contains 114 tables, charts and graphs that add visual analysis in order to explain developing trends within the Systemic Lupus Erythematosus market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading SLE submarkets, segmented by product, including forecasts for Atacicept, Benlysta, Anifrolumab, Lulizumab, Bisibimod, CellCept and Prograf. The SLE market is also segmented by Molecule Type, with forecasts for Small Molecules, Monoclonal Antibodies and Recombinant Proteins. The market is also segmented by pharmacological class, with forecasts for B-Cell Targeting Therapies, Interferon Receptor Antagonists, CD Antagonist Therapies and other Therapies for SLE.
The 152-page report offers market forecasts and analysis for 2 regional and 9 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 6 companies leading the SLE field in detail.
The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography report will be of value to anyone who wants to better understand the SLE market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the systemic lupus erythematosus therapy industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.